Drs. Sanjiv Shah (overall for PI HeartShare DTC) and Frank Heinzel have outlined the future of heart failure with preserved ejection fraction (HFpEF) in a recently published article in Herz, titled “The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics.” This article explores many topics the AMP Heart Failure program seeks to address.

Here we provide a framework for understanding the phenotype-based approach to HFpEF by reviewing (1) the historical context of HFpEF; (2) the current HFpEF paradigm of comorbidity-induced inflammation and endothelial dysfunction; (3) various methods of sub-phenotyping HFpEF; (4) comorbidity-based classification and treatment of HFpEF; (5) machine learning approaches to classifying HFpEF; (6) examples from HFpEF clinical trials; and (7) the future of phenomapping (machine learning and other advanced analytics) for the classification of HFpEF.

Heinzel FR, Shah SJ. The future of heart failure with preserved ejection fraction : Deep phenotyping for targeted therapeutics. Herz. 2022 Aug;47(4):308-323. doi: 10.1007/s00059-022-05124-8. Epub 2022 Jun 29. PMID: 35767073; PMCID: PMC9244058.

The full text of the article can be found here: https://link.springer.com/article/10.1007/s00059-022-05124-8